Research and Markets: EpiCast Report: Diabetic Nephropathy - Epidemiology Forecast to 2022

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/rl59f2/epicast_report) has announced the addition of the "EpiCast Report: Diabetic Nephropathy - Epidemiology Forecast to 2022" report to their offering.

Diabetic nephropathy is one of the microvascular complications of diabetes, along with diabetic neuropathy and diabetic retinopathy. With the increasing prevalence of diabetes around the world, diabetic nephropathy is the most common type of chronic kidney disease (KDOQI, 2007; Zimmet et al., 2001).

When diabetes is not properly controlled, the high concentration of glucose in the blood overloads the kidneys, causing the kidneys to filter too much blood. When uncontrolled diabetes persists for 15 to 25 years, the blood vessels in the kidneys become damaged, resulting in abnormal amounts of albumin in the urine and a reduced glomerular filtration rate (GFR). Diabetic nephropathy eventually progresses to end-stage renal disease (ESRD), or kidney failure, which requires dialysis or kidney transplantation (ADA, 2013; CDA, 2012; NHS, 2011; NKUDIC, 2013).

In this report, The authors epidemiologists utilized nationally-representative data from peer-reviewed journals to provide the total prevalent cases of diabetic nephropathy in the diagnosed diabetic population in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). Moreover, the forecast methodology was consistent across all of the 7MM in order to allow for a meaningful comparison of the total prevalent cases of diabetic nephropathy in these markets.

In 2012, there were 14.03 million total prevalent cases of diabetic nephropathy in the diagnosed diabetic population in the 7MM, with approximately 44% of the total prevalent cases (6.1 million total prevalent cases) being in the US alone. The authors epidemiologists forecast that there will be 19.87 million total prevalent cases of diabetic nephropathy in the diagnosed diabetic population in the 7MM by 2022, with an annual growth rate (AGR) of 4.16% during the forecast period.

The authors epidemiologists forecast an increase in the total prevalent cases of diabetic nephropathy in the diagnosed diabetic population in each of the 7MM due to an increase in the prevalence of diagnosed diabetics in the 7MM.

Key Topics Covered:

1.1 List of Tables

1.2 List of Figures

2 Introduction

3 Epidemiology

4 Appendix

For more information visit http://www.researchandmarkets.com/research/rl59f2/epicast_report

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals